Cytokines enhance human Vγ9Vδ2 T-cell TCR-dependent and TCR-independent effector functions

Eur J Immunol. 2023 Jun;53(6):e2250220. doi: 10.1002/eji.202250220. Epub 2023 Apr 13.

Abstract

Vγ9Vδ2 T cells can recognize various molecules associated with cellular stress or transformation, providing a unique avenue for the treatment of cancers or infectious diseases. Nonetheless, Vγ9Vδ2 T-cell-based immunotherapies frequently achieve suboptimal efficacies in vivo. Enhancing the cytotoxic effector function of Vγ9Vδ2 T cells is one potential avenue through which the immunotherapeutic potential of this subset may be improved. We compared the use of four pro-inflammatory cytokines on the effector phenotype and functions of in vitro expanded Vγ9Vδ2 T cells, and demonstrated TCR-independent cytotoxicity mediated through CD26, CD16, and NKG2D, which could be further enhanced by IL-23, IL-18, and IL-15 stimulation throughout expansion. This work defines promising culture conditions that could improve Vγ9Vδ2 T-cell-based immunotherapies and furthers our understanding of how this subset might recognize and target transformed or infected cells.

Keywords: TCR-independent cytotoxicity; Vγ9Vδ2 T cells; cellular activation; human γδ T cells; pro-inflammatory cytokines.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Proliferation
  • Cytokines / metabolism
  • Humans
  • Receptors, Antigen* / immunology
  • T-Lymphocytes* / cytology
  • T-Lymphocytes* / metabolism

Substances

  • Cytokines
  • Receptors, Antigen